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Key Points 56 
Question Does intensive blood pressure lowering increases the risk of mortality in chronic 57 
kidney disease patients? 58 
 59 
Findings In this meta-analysis among 18 randomized trials comprising 15,924 chronic kidney 60 
disease patients, more intensive blood pressure lowering was associated with significantly 61 
decreased risk of mortality in comparison to less-intensive blood pressure control. 62 
 63 
Meaning Targeting more intensive blood pressure may provide mortality benefit in persons with 64 
chronic kidney disease. 65 
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Abstract 66 
Importance: Trials in hypertensive patients demonstrate that intensive blood pressure (BP) 67 
lowering reduces risk of cardiovascular disease (CVD) and all-cause mortality, but may increase 68 
risk of chronic kidney disease (CKD) incidence and progression.  Whether intensive BP lowering 69 
is associated with a mortality benefit in patients with prevalent CKD remains unknown.  70 
 71 
Objective: We conducted a meta-analysis of Randomized controlled trials (RCTs) to determine 72 
if more intensive, compared with a less intensive, BP control is associated with reduced 73 
mortality risk in persons with CKD stages 3-5.  74 
 75 
Data Sources: Ovid Medline, Cochrane Library, Embase, Pubmed, Science Citation Index, 76 
Google Scholar, and ClinicalTrials.gov electronic databases. 77 
 78 
Study Selection: All RCTs that compared two defined BP targets (either active treatment vs. 79 
placebo or no treatment, or intensive vs. less intensive BP control) and enrolled adult (≥18 80 
years) persons with CKD stages 3-5 (estimated glomerular filtration rate (eGFR) <60 81 
mL/min/1.73m2) exclusively or that included a CKD subgroup between January 1950 and June 82 
2016 were included.  83 
 84 
Data extraction and synthesis: Two reviewers independently evaluated study quality and 85 
extracted characteristics and mortality events among persons with CKD within the intervention 86 
phase for each trial.  When outcomes within the CKD group had not previously been published, 87 
we contacted trial investigators and requested data within the CKD subset of their original trials.   88 
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Main outcomes and measures: All-cause mortality during the active treatment phase of each 89 
trial. 90 
 91 
Results: We identified 30 RCTs that potentially met inclusion criteria, among which we were 92 
able to extract the CKD subset mortality data in 18 trials. Among these, there were 1293 deaths 93 
among 15,924 participants with CKD. The mean baseline systolic blood pressure (SBP) was 94 
148±16 mm hg in both intensive and less-intensive arms. The mean SBP dropped by 16 mm Hg 95 
to 132 mm Hg in the intensive arm and by 8 mm Hg to 140 mm Hg in the less-intensive arm. 96 
More vs. less-intensive BP control resulted in 14% lower risk of all-cause mortality (Odds Ratio 97 
(OR) 0.86; 95% CI 0.76 to 0.97, p = 0.01); a finding that was without significant heterogeneity 98 
and appeared consistent across multiple subgroups  including type of treatment in the 99 
comparator arm (placebo vs. less intensive BP target), length of follow-up, presence of 100 
diabetes, CKD severity, baseline systolic blood pressure (SBP), achieved SBP during the trial 101 
and degree of SBP differences across the treatment arms. 102 
 103 
Conclusion and Relevance: Randomization to more intensive BP control is associated with 104 
lower mortality risk among trial participants with hypertension and CKD. Further studies are 105 
required to define absolute BP targets for maximal benefit and minimal harm. 106 
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Introduction 107 
     Chronic kidney disease (CKD) is a major public health problem estimated to affect 26 million 108 
Americans and 200 million individuals worldwide.1,2 Persons with CKD are at high risk for 109 
cardiovascular disease (CVD), progression to end stage renal disease (ESRD), and all-cause 110 
mortality3. Hypertension is a well-known risk factor for CVD and thus optimal blood pressure 111 
(BP) control is a major clinical and public health priority.4,5 Over the past decade, several studies 112 
and clinical practice guidelines have addressed the optimal BP target in CKD populations 6-10, 113 
yet consensus remains elusive. Observational data have demonstrated U shaped relationships 114 
between BP and mortality risk among those with CKD.11,12 Clinical trials testing different BP 115 
targets in CKD populations including the Modification of Diet in Renal Disease (MDRD) and 116 
African American Study of Kidney Disease and Hypertension (AASK) failed to demonstrate 117 
benefits of BP lowering for slowing down CKD progression, and were underpowered to address 118 
CVD and mortality.13,14 119 
      The current Kidney Disease Improving Global Outcomes (KDIGO) BP guidelines 120 
recommend a BP goal of less than 130/80 mmHg for individuals with CKD and moderate-to-121 
severe albuminuria and less than 140/90 mmHg for those with CKD and albuminuria <30 mg/g7. 122 
The Eighth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of 123 
High Blood Pressure (JNC 8) and the 2013 European Society of Hypertension/European 124 
Society of Cardiology Task Force concluded that BP target less than 140/90 mmHg for 125 
individuals with CKD, and made no distinction based on the albuminuria level.15,16 These 126 
guidelines were published before The Systolic Blood Pressure Intervention Trial (SPRINT) was 127 
completed. The SPRINT study enrolled hypertensive individuals without diabetes and with high 128 
CVD risk, and found a substantially lower CVD risk and lower all-cause mortality risk in 129 
participants treated to a SBP target of less than 120 mmHg as compared with less than 130 
140 mmHg, though with a significant excess of acute kidney injury (AKI).17 Patients with CKD 131 
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(defined as eGFR 20-59 ml/min/1.73 m2) accounted for approximately 30% of SPRINT trial 132 
participants, and the results were similar (no statistically significant interactions) among those 133 
with CKD compared with their non-CKD counterparts.  However, the trial was not specifically 134 
powered to define the risks and benefits of intensive BP control for those with CKD.  135 
     The different definitions and differential reporting of AKI, CKD progression, and CVD events 136 
from previous randomized control trials represent a major challenge to comprehensively 137 
address these endpoints in a meta-analysis. In contrast, mortality is similarly defined across 138 
studies, and is virtually always reported as it is an important safety signal.  Mortality also 139 
provides a summary estimate of net benefits and harms of the intervention.  Thus, our goal was 140 
to determine the effect of more intensive BP control on mortality among those with CKD.   141 
 142 
Methods 143 
Electronic searches 144 
    The Ovid MEDLINE, Cochrane Library, Embase, Pubmed, Science Citation Index, Google 145 
Scholar, and ClinicalTrials.gov electronic databases searches were completed from January 1, 146 
1950 to June 1, 2016, with the following key words: “randomized controlled trials,” ”intensive 147 
blood pressure treatment,” “intensive blood pressure control,” “strict blood pressure treatment,” 148 
“strict blood pressure control,” “tight blood pressure treatment” or “tight blood pressure 149 
control”.18 The detailed database search strategy is described in the study protocol. The 150 
ClinicalTrials.gov website was searched for randomized trials that were registered as completed 151 
but not yet published. The reference articles from each identified trial were reviewed to identify 152 
any additional relevant studies. No language restrictions were applied. The literature search was 153 
performed according to the Preferred Reporting Items for Systematic Meta-Analyses (PRISMA) 154 
statement recommendations (Table S3).19 155 
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Selection of Studies 156 
     Study eligibility was individually determined by two independent reviewers (RM and AN). 157 
Both open-label and double-blinded randomized controlled trials (RCT) who had adult 158 
participants with CKD, which was defined as eGFR < 60 mL/min per 1.73m2 by either the 159 
Modification of Diet in Renal Disease (MDRD) or Chronic Kidney Disease Epidemiology 160 
Collaboration (CKD-EPI) equations, and had randomized participants to two defined BP targets 161 
(either BP intervention vs. placebo or no treatment, or more vs. less intensive BP control), were 162 
eligible for inclusion. In some instances, identified trials included persons with CKD, but the 163 
trials had not previously published mortality events within the CKD subset.  In such cases, we 164 
contacted the study investigators and requested data on the number of patients with CKD 165 
enrolled in the trial, the number in each treatment arm, and the number of deaths that occurred 166 
during the active trial phase. Studies in dialysis patients were excluded. 167 
 168 
Data Extraction and Quality Assessment  169 
     Demographics, co-morbid characteristics, enrollment criteria, BP control targets in each arm, 170 
mean reductions of systolic and diastolic BP, and mortality events were extracted onto 171 
standardized extraction forms. Extracted data was then veriﬁed by another researcher. For any 172 
discrepancies, both investigators met, conferred, and consensus was reached. The quality and 173 
clinical generalizability of each study was assessed according to the methods based on 174 
allocation concealment, blinding methods of participants, investigators and assessors, intention 175 
to treat analysis, percent withdrawals, and whether withdrawals were adequately described.20  176 
 177 
Outcome Measures 178 
    The primary outcome was all-cause mortality during the active treatment phase of each trial. 179 
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Statistical Analysis 180 
     Mortality outcomes in each randomized BP group were pooled and weighted odds ratio 181 
(OR), comparing the lower BP arm (intensive BP) to subjects randomized to higher BP targets 182 
(less intensive or placebo), and their 95% conﬁdence intervals (CI) were calculated using both 183 
random and fixed-effect models. The influence of individual trials on pooled effect size was 184 
assessed, and the trial was considered to have an excessive influence if, after its exclusion, the 185 
point estimate of the remaining trials was outside the confidence interval of the overall risk 186 
estimate. Heterogeneity was assessed based on I2 test (I2= 0-25%: no or mild heterogeneity; I2= 187 
25-50%: moderate heterogeneity; I2= 50-75%: large heterogeneity; and I2= 75-100%: extreme 188 
heterogeneity).20 Subgroup analyses were performed stratified by type of study (drug vs. 189 
placebo vs. two defined BP target arms), study trial duration, diabetes status (yes or no), 190 
baseline SBP, the level of achieved SBP during the trial phase, and the SBP difference between 191 
the two randomized arms. Meta-regression analysis was performed to assess the relation 192 
between the SBP differences during the trial phase and mortality risk while adjusting for 193 
baseline SBP. Potential publication bias was assessed using Funnel plots. A p-value < 0.05 was 194 
considered statistically significant for all analyses including tests for heterogeneity. All statistical 195 
analyses were performed using the Comprehensive Meta-Analysis software version 2.2.064 196 
(Biostat Inc, NJ, USA). 197 
 198 
Results 199 
Literature search 200 
     The initial search of the Ovid MEDLINE and Cochrane databases between January 1, 1950 201 
and June 1, 2016 provided 4,416 citations. We reviewed abstracts and limited this search to a 202 
more detailed review of 407 abstracts of studies potentially eligible for inclusion as described in 203 
method section.  In subsequent review, 378 studies were discarded because they did not fulfill 204 
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inclusion criteria. The remaining 30 studies were reviewed in full text and identified for meta-205 
analysis (Figure 1). Data elements from nine trials were extracted from the publications. 13,14,17, 206 
21-27  We contacted trial investigators for the remaining trials and nine provided data on number 207 
of CKD participants and deaths during the trial phase for the two BP arms for the purpose of 208 
inclusion in this meta-analysis.28-36  Among the others, we were unable to obtain mortality data 209 
in the CKD subset from the investigators for the remaining 12 trials.37-48 Thus, eighteen 210 
randomized trials involving 15,924 participants with CKD and complete data were included in 211 
the meta-analysis (Figure 1).  212 
 213 
Study Characteristics 214 
     Table S1 summarizes the main characteristics of the studies included in the meta-analysis. 215 
All trials were of good quality. Each used a parallel treatment group design and fifteen trials 216 
reported adequate methods for random allocation and concealment of treatment assignment 217 
(Table S2).  There were six trials that had excluded patients with insulin-dependent diabetes 218 
mellitus (IDDM)13,22,26-28,35 whereas three trials excluded patients with all forms of diabetes.14,17,23 219 
Thirteen of the eighteen trials had two defined BP targets13,14,17,22-25,31-36 and the remaining five 220 
evaluated a BP lowering intervention vs. no treatment or a placebo arm.26-30 One trial has three 221 
defined BP targets.  For the purposes of this meta-analysis, the lowest BP target group was 222 
compared to the other two groups together.36 BP targets varied across trials (Table 1). The 223 
median (interquartile range (IQR)) baseline SBP was 143 (137-162) mm Hg in the intensive and 224 
153 (137-163) mm Hg in the less intensive arms. The median (IQR) follow-up period was 3.6 225 
(2.8-4.9) years.  The median (IQR) difference in SBP achieved across arms among 18 adult 226 
trials was 10 (4-12) mm Hg (130 (125-141) mm hg in intensive vs. 138 (134-146) mm Hg in 227 
less-intensive arm).13,14,17,22-36 The renal inclusion and exclusion criteria varied across trials and 228 
are described in Table S1. 229 
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BP control and risk of mortality 230 
     Figure 2 depicts the main results of the meta-analysis.  In the eighteen included trials, there 231 
were 584 deaths among 7,451 participants (7.8%) in the more intensive BP arm and 709 deaths 232 
among 8,473 participants (8.4%) in the less intensive BP arm during the trial phase.  Using the 233 
random-effect model, the odds ratio (OR) for death among participants with CKD randomized to 234 
the intensive BP lowering arm was 0.86 (95% CI, 0.76 to 0.97, p = 0.01) compared to the less 235 
intensive BP arm. The results were similar with the fixed-effect model. None of the individual 236 
trials have excessive influence on pooled effect size. Since we new a priori that SPRINT had 237 
found that intensive BP control improved mortality, and provides substantial power to this meta-238 
analysis, we specifically evaluated the remaining trials excluding SPRINT in a sensitivity 239 
analysis.  Results were similar in this analysis (HR 0.88, 95% CI 0.78 to 0.99, p = 0.05). There 240 
was no evidence of heterogeneity across studies (I2 = 0.0%, p-heterogeneity = 0.77).  Funnel-241 
plot analysis revealed no evidence of publication bias based on visual inspection (Figure 3) or 242 
by performing Begg and Mazumdar rank correlation (p = 0.23) and Egger’s regression (p = 243 
0.08) tests.  244 
 245 
Subgroup analysis 246 
     The observed effect of those randomized to the more intensive BP arm on mortality was 247 
consistent irrespective of the type of treatment in the comparator arm (placebo or less intensive 248 
BP target), median follow-up duration (< 3 years vs. ≥ 3 years), diabetic status (yes or no), CKD 249 
severity ( sCR < 2.0 mg/dL or creatinine clearance < 30 ml/min vs sCR >2.0 mg/dL or creatinine 250 
clearance > 30 ml/min), baseline SBP of the entire cohort (<140 mm Hg vs. 140-160 mm Hg vs. 251 
> 160 mm Hg), or achieved SBP in the intensive lowering group (SBP <125 mmHg vs. SBP 252 
125-135 mm Hg vs. SBP > 135 mm Hg) (Figure 4). In the trials that achieved a difference in 253 
SBP ≥ 12 mm Hg, the odds of death in the more intensive vs. less intensive arm was 0.76; trials 254 
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with differences > 6 to <12 mm Hg had an OR of 0.97; and those with differences ≤ 6 mm Hg 255 
had an OR for mortality of 1.06; formal testing for heterogeneity approached statistical 256 
significance (p=0.062). Meta-regression adjusting for baseline SBP level, showed a similar 257 
pattern trending towards greater mortality benefit in trials with greater differences in achieved 258 
BP across treatment arms, although this finding did not reach statistical significance (slope of 259 
log OR per mm Hg difference in SBP -0.0201, 95% CI, -0.0499 to 0.0097, p= 0.19) (Figure S1). 260 
 261 
Discussion 262 
     In this meta-analysis of eighteen randomized controlled trials among 15,924 participants with 263 
both hypertension and an eGFR < 60 ml/min/1.73m2 randomization to more vs. less intensive 264 
BP lowering, those randomized to more intensive BP lowering had 14% lower risk of all-cause 265 
mortality.  We observed a trend towards mortality benefit in studies that achieved the greatest 266 
separation in SBP between the two treatment arms especially ≥ 12 mm Hg (p=0.062).  These 267 
findings add to the body of evidence which may inform public health policy, clinical guideline 268 
development, and individual patient care in patients with CKD. 269 
     A prior meta-analysis found beneficial effects in persons randomized to more intensive BP 270 
lowering on CVD events among patients with CKD (26 trials, 30 295 participants, hazard ratio 271 
(HR) 0.83; 95% CI 0.76 to 0.90).49 CVD events are extremely important, and are the major 272 
cause of death in those with CKD.  However, we evaluated all-cause mortality as it balances the 273 
competing risk of multiple clinical outcomes and because it is a “hard” outcome assessed 274 
similarly across studies.  For example, if intensive BP lowering leads to higher risk of AKI and 275 
potential CKD progression but lower risk of CVD events, these outcomes could offset one 276 
another resulting in no overall effect on all-cause mortality. This consideration is particularly 277 
important in persons who have CKD at baseline.  Less residual kidney function may make 278 
participants with CKD particularly vulnerable to additional insults resulting in loss of kidney 279 
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function, as has been reported in multiple clinical trials evaluating intensive BP control.17,50 280 
Though the results from recent meta-analysis showed that intensive BP lowering was protective 281 
against kidney failure events especially in patients with CKD and proteinuria.21 Another study in 282 
AASK and MDRD trial also showed that 5% to <20% acute decline in eGFR in intensive BP arm 283 
was not associated with a higher risk of ESRD (adjusted hazard ratio (aHR), 1.19; 95% % CI 284 
0.84 to 1.68) and (aHR, 1.08; 95% CI, 0.84 to 1.40), respectively) were as similar changes in 285 
the less intensive group were associated with ESRD (aHR, 1.83; 95% % CI 1.30 to 2.57) and 286 
(aHR, 1.62; 95% CI, 1.25 to 2.11), respectively.51  The results of our meta-analysis, therefore, 287 
suggest that intensive BP control may provide more benefit than harm in persons with CKD. 288 
     Approximately 30% of SPRINT study participants had CKD at baseline.17 The primary 289 
endpoint of the SPRINT trial was a composite CVD endpoint.  While the p-value for interaction 290 
for the primary CVD endpoint comparing those with and without CKD was not statistically 291 
significant (p=0.36), the effect estimate was smaller and did not reach statistical significance in 292 
the CKD subgroup (HR 0.82; 95% CI 0.63 to 1.07).  Moreover, intensive BP control resulted in a 293 
higher risk of a 30% decline in eGFR among those without CKD, and more rapid loss of eGFR, 294 
and higher AKI events in SPRINT participants both with and without CKD at baseline.17       295 
Interestingly, in the SPRINT trial, those with CKD randomized to the intensive BP lowering arm 296 
had a statistically significant reduction in all-cause mortality (HR 0.72; 95% CI, 0.52 to 0.98; p= 297 
0.04). However, the total number of death events in the SPRINT CKD subgroup were relatively 298 
low (70 deaths among 1330 individuals in intensive-BP group vs. 95 deaths among 1,336 in the 299 
standard-treatment group) and the trial excluded persons with diabetes, proteinuria greater than 300 
1000 mg/g, and prior stroke.  Whether results generalize to these other subsets, and whether 301 
the mortality benefit observed in SPRINT participants with CKD is reproducible was previously 302 
unknown. The present meta-analysis extends these findings, and provides additional 303 
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assurances in a larger study sample and across different settings.  Overall, we observed little 304 
heterogeneity across studies.  305 
    We observed a trend towards the greatest mortality benefit in studies that achieved the 306 
greatest separation in SBP during the trial; a finding that did not reach statistical significance 307 
(p=0.062).  These data will need to be re-evaluated when additional trials evaluating intensive 308 
BP control among those with CKD are completed.  Nonetheless, this preliminary finding 309 
supports our overall conclusion that more intensive BP control may be beneficial for those with 310 
CKD. The size of the mortality reduction in CKD patients (14%) is similar to that (9% and 11%) 311 
calculated in a recent meta-analysis of all BP-lowering trials52,53, and this suggests the benefits 312 
of BP lowering in all-cause mortality do not differ substantially in presence or absence of CKD.  313 
     The findings of this meta-analysis may have implications to both clinical practice and public 314 
health policy.  In regards to public policy, the KDIGO recently announced that they have 315 
convened a panel of experts to review evidence and potentially modify their guideline 316 
recommendations regarding appropriate blood pressure targets in patients with CKD.54   This 317 
meta-analysis may provide useful data for the upcoming guideline review.  Our findings may 318 
also provide additional information for patients and healthcare providers, and may be useful to 319 
guide shared decision making about the relative risks and benefits of blood pressure lowering 320 
among those with CKD. 321 
     This study has several strengths. First, multiple high-quality, methodologically rigorous 322 
randomized trials had not previously reported differences in death rates across treatment arms 323 
in persons with prevalent CKD.   Among the eighteen studies included in this meta-analysis, 324 
investigators from nine trials re-evaluated their data within the CKD subset and provided data 325 
specifically to support this study.  Thus, this manuscript provides a substantial new evidence 326 
base about the risks and benefits of intensive BP lowering in populations with CKD. Second, we 327 
assessed mortality as a hard clinical outcome which has obvious clinical importance and is 328 
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similarly ascertained across studies and is therefore largely free of bias. In addition, we 329 
restricted our analysis to outcomes that were assessed during the trial phase of each study 330 
only, and excluded events that occurred during long-term follow-up.  While there is important 331 
information obtained in long-term follow-up55,56, BP control often approached similar levels 332 
across treatment arms after the trial phase.55 333 
     Our study also has important limitations. Despite considerable efforts to contact 334 
investigators, we were not able to obtain data on mortality in persons with CKD in several prior 335 
clinical trials.  These trials were therefore excluded by necessity.  However, among the nineteen 336 
studies with nearly 16,000 CKD participants, we found no evidence of heterogeneity.  This 337 
provides confidence, although not certainty, that results would likely have been similar with 338 
inclusion of additional studies. Next, we lacked data by strata of CKD, and therefore could not 339 
evaluate the effect of more intensive BP lowering on mortality stratified by CKD severity. Most 340 
individuals in the included trials had CKD stage 3, and we acknowledge that the risks and 341 
benefits of more intensive BP lowering may differ in persons with more advanced CKD. Fourth, 342 
baseline BP, and the intensity of BP reduction in the randomized treatment arms were different 343 
across the individual trials.  As such, we are not able to provide an estimate of an optimal BP 344 
target in CKD patients.  We recognize that CVD events, CKD progression, AKI and ESRD 345 
events are important factors that may be in the causal pathway between more intensive BP 346 
lowering and mortality, and were not able to assess these endpoints.   347 
      348 
Conclusions 349 
     Among trial participants with hypertension and an eGFR < 60 ml/min/1.73m2, randomization 350 
to more intensive BP lowering was associated with lower risk of all-cause mortality. This finding 351 
was consistent across trials with no evidence of heterogeneity.  A non-significant trend towards 352 
greater mortality benefit was observed in trials that achieved the greatest difference in SBP 353 
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across arms.  Although additional studies and intensive monitoring for safety are warranted, 354 
these data support the notion that the net benefits may outweigh net harms of more intensive 355 
BP lowering in persons with CKD. 356 
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Figure Legends 539 
Figure 1: Title: Selection of Studies for the Meta-Analysis. Legend: None. 540 
Figure 2: Title: Effect of Intensive Blood Pressure Lowering on Risk of Mortality in Hypertensive 541 
Trial Participants with CKD. Legend: None. 542 
Figure 3: Title: Funnel Plot of Studies Evaluating Intensive Blood Pressure Control in Relation 543 
to Mortality among Persons with CKD. Legend: A symmetrical inverted funnel implies no 544 
publication bias. Each open circle represents individual published study. 545 
Figure 4: Title: Effect of More Intensive Blood Pressure Lowering on Risk of Mortality in 546 
Patients with CKD, Stratified by Subgroups. Legend: None. 547 
Figure S1: Title: Random Effects Meta-Regression Plot Depicting Risk of Mortality by 548 
Magnitude of Difference in Systolic Blood Pressure (SBP) Achieved Across Randomization 549 
Arms, Adjusting for Baseline SBP. Legend: Slope= -0.0201, 95% CI, -0.0499 to 0.0097, P= 550 
0.19. The plot shows the correlation between differences in SBP (plotted as a mean value on 551 
the x-axis) and the probability of mortality (log OR) (plotted on the y-axis). Each circle 552 
represents an individual study, and the circumference of each circle is proportional to the 553 
sample size of each study. OR= odds ratio. 554 
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Figure 1 
Study name Statistics for each study Dead / Total Odds ratio and 95% CI
Odds Lower Upper More Less 
ratio limit limit Z-Value p-Value Intensive BP Intensive BP
AASK (14) 0.874 0.554 1.380 -0.578 0.564 37 / 540 43 / 554
ABCD (H) (24) 0.575 0.182 1.820 -0.941 0.347 5 / 62 9 / 68
ABCD (N) (26) 1.227 0.389 3.865 0.349 0.727 6 / 57 7 / 80
ACCORD (32) 1.271 0.685 2.360 0.761 0.447 26 / 208 20 / 198
ADVANCE (27) 0.862 0.662 1.123 -1.102 0.270 117 / 1010 135 / 1023
HOT (37) 0.993 0.699 1.410 -0.039 0.969 49 / 1220 97 / 2399
HYVET (30) 0.676 0.502 0.911 -2.570 0.010 83 / 788 121 / 816
MDRD (13) 1.366 0.681 2.742 0.878 0.380 20 / 432 14 / 408
PAST-BP (34) 3.588 0.140 91.945 0.772 0.440 1 / 26 0 / 30
REIN-2 (22) 0.667 0.110 4.042 -0.441 0.659 2 / 167 3 / 168
SCHRIER (25) 0.825 0.050 13.701 -0.134 0.893 1 / 41 1 / 34
SHEP (28) 0.900 0.670 1.209 -0.700 0.484 96 / 879 103 / 859
SPRINT (17) 0.714 0.519 0.982 -2.072 0.038 70 / 1330 95 / 1316
SPS3 (35) 0.850 0.468 1.544 -0.534 0.594 24 / 216 25 / 195
SYS-EUR (29) 0.826 0.470 1.451 -0.665 0.506 26 / 242 29 / 228
TOTO (23) 2.566 0.101 64.993 0.572 0.568 1 / 42 0 / 35
UKPDS (35) 1.667 0.626 4.435 1.023 0.306 20 / 68 7 / 35
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